Aridis Pharmaceuticals, Inc. today announced the pricing of an offering of 10,000,000 shares of the Company's common stock (or pre-funded warrants in lieu thereof) and accompanying warrants to purchase up to 10,000,000 shares of common stock at a combined offering price of $0.20 per share.
Aridis is a California-based biopharmaceutical company that discovers and develops novel anti-infective therapies for the treatment of respiratory infections.